Skip to main content

Cost of Osteoporosis Care in the USA

The 2010 NHANES study suggests that the overall prevalence of osteoporosis (OP) in the USA is ~10% or 10.2 million older adults (> 50 yrs) had osteoporosis.  This combined with the ~44% prevalence of low bone mass (43.4 million) highlights the public health problem of OP and osteopenia in the USA.

An analysis by the NIH-NIAMS shows that $990 million dollars was spent on anti-osteoporosis drugs in 2013. 

This data is based on Medicare patients receiving anti-osteoporotic therapy in 2013. $756 million (77%) was attributable to brand name drugs. Generic dispensing rate varied from 57-86% across the different states in the USA. 

Despite this cost, only one in two adults with osteoporosis aged 65 and older received a prescription for an anti-osteoporosis drug.

Thirty-eight percent of the total prescriptions from orthopedic surgeons were for Forteo® or Prolia® compared to 12.5 % from specialists.

These findings highlight the need for ongoing training for physicians who engage in the care of patients with osteoporosis to manage the disease in a cost-effective manner.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject